Bio-Rad Laboratories, Inc. (BIO) Shares Bought by Levin Capital Strategies L.P.
Levin Capital Strategies L.P. raised its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 7,126.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 569,205 shares of the medical research company’s stock after acquiring an additional 561,328 shares during the period. Bio-Rad Laboratories accounts for 2.9% of Levin Capital Strategies L.P.’s portfolio, making the stock its 11th largest position. Levin Capital Strategies L.P.’s holdings in Bio-Rad Laboratories were worth $132,181,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Atria Investments LLC acquired a new stake in shares of Bio-Rad Laboratories during the 3rd quarter worth approximately $337,000. We Are One Seven LLC acquired a new stake in Bio-Rad Laboratories in the 3rd quarter valued at $254,000. First Hawaiian Bank acquired a new stake in Bio-Rad Laboratories in the 3rd quarter valued at $713,000. Nisa Investment Advisors LLC boosted its stake in Bio-Rad Laboratories by 475.7% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,209 shares of the medical research company’s stock valued at $378,000 after buying an additional 999 shares in the last quarter. Finally, Oakbrook Investments LLC boosted its stake in Bio-Rad Laboratories by 36.8% in the 3rd quarter. Oakbrook Investments LLC now owns 2,600 shares of the medical research company’s stock valued at $814,000 after buying an additional 700 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
Shares of BIO opened at $248.85 on Monday. The company has a quick ratio of 3.16, a current ratio of 4.49 and a debt-to-equity ratio of 0.09. Bio-Rad Laboratories, Inc. has a 52-week low of $220.05 and a 52-week high of $345.15. The firm has a market capitalization of $7.46 billion, a price-to-earnings ratio of 60.70, a price-to-earnings-growth ratio of 2.45 and a beta of 1.21.
Several analysts recently commented on BIO shares. Goldman Sachs Group started coverage on Bio-Rad Laboratories in a research note on Wednesday, October 17th. They issued a “buy” rating and a $350.00 price target on the stock. Barclays decreased their price target on Bio-Rad Laboratories from $345.00 to $315.00 and set an “equal weight” rating on the stock in a research note on Friday, November 2nd. Finally, Zacks Investment Research raised Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 3rd. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. Bio-Rad Laboratories presently has an average rating of “Buy” and a consensus target price of $338.43.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
Read More: Why do company’s buyback their stock?
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.